Novel drugs in the management of difficult-to-treat hepatitis C genotypes
Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates...
Guardado en:
Autores principales: | Cartwright EJ, Miller L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013) -
Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
por: Gomaa A, et al.
Publicado: (2017) -
Difficult bile duct cannulation: Do all roads lead to Rome?
por: Marianna Arvanitakis
Publicado: (2021) -
Hepatitis C in Argentina: epidemiology and treatment
por: Gaite LA, et al.
Publicado: (2014) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
por: JIANG Yingying
Publicado: (2021)